Skip to main content

Advertisement

SpringerLink
Log in

Cefepime Dosing in the Morbidly Obese Patient Population

  • Clinical Report
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Proper dosing of specific antibiotics in morbidly obese patients has been studied inadequately. However, these data are beneficial as this patient population is at an increased risk to develop postoperative infections. Cefepime is an antibiotic used for the treatment of both gram-positive and especially gram-negative infections; administration of the appropriate dose in the morbidly obese population is crucial. We therefore examined the pharmacokinetics of cefepime in patients with body mass index >40 kg/m2. Ten morbidly obese patients, with a mean [±SD] estimated glomerular filtration rate of 108.4 ± 34.6 mL/min, undergoing elective weight loss surgical procedures were administered cefepime in addition to standard prophylactic cefazolin and studied. Serial serum cefepime concentrations were analyzed after dosing using a validated high performance liquid chromatography method. Pharmacokinetics and duration above the minimum inhibitory concentration (MIC) were determined using a protein binding value of 15% and a MIC threshold of 8 μg/mL. Mean free cefepime concentrations for t = 30, 120, and 360 min were 69.6, 31.6, and 9.2 μg/mL, respectively. The dosing interval was calculated to maintain the free concentration above the MIC (fT > MIC) for 60% of the interval. This was determined to be 10.12 h, including time for infusion. There was no toxicity. Based on this analysis, an increased dose of 2 g every 8 h is necessary to maintain an adequate fT > MIC throughout the dosing interval. Further studies are necessary to determine the efficacy of this regimen in the settings of active infections and critical illness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. World Health Organization. Obesity and overweight. Fact sheet 311. September 2006.

  2. Choban PS, Heckler R, Burge JC, et al. Increased incidence of nosocomial infections in obese surgical patients. Am Surg. 1995;61:1001–5.

    PubMed  CAS  Google Scholar 

  3. Canturk Z, Canturk NZ, Cetinarslan B, et al. Nosocomial infections and obesity in surgical patients. Obes Res. 2003;11:769–75.

    Article  PubMed  Google Scholar 

  4. Barie PS, Eachempati SR. Surgical site infections. Surg Clin North Am. 2005;85:1115–35.

    Article  PubMed  Google Scholar 

  5. Bamgbade OA, Rutter TW, Nafiu OO, et al. Postoperative complications in obese and nonobese patients. World J Surg. 2007;31:556–60.

    Article  PubMed  Google Scholar 

  6. Nasraway Jr SA, Albert M, Donnelly AM, et al. Morbid obesity is an independent determinant of death among surgical critically ill patients. Crit Care Med. 2005;34:964–70.

    Article  Google Scholar 

  7. Dindo D, Muller MK, Weber M, et al. Obesity in general elective surgery. Lancet. 2003;361:2032–5.

    Article  PubMed  Google Scholar 

  8. Greenberg JA, Robinson MK. Surgery: how safe is bariatric surgery? Nat Rev Endocrinol. 2009;5:645–6.

    Article  PubMed  Google Scholar 

  9. Olsen MA, Nepple JJ, Riew KD, et al. Risk factors for surgical site infection following orthopaedic spinal operations. J Bone Joint Surg Am. 2008;90:62–9.

    Article  PubMed  Google Scholar 

  10. Gillespie EL, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials: treatment optimization. Expert Opin Drug Metab Toxicol. 2005;1:351–61.

    Article  PubMed  CAS  Google Scholar 

  11. Edmiston Jr CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery. 2004;136:738–47.

    Article  PubMed  Google Scholar 

  12. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988;84:1053–60.

    Article  PubMed  CAS  Google Scholar 

  13. Pieracci FM, Barie PS, Pomp A. Critical care of the bariatric patient. Crit Care Med. 2006;34:1796–804.

    Article  PubMed  Google Scholar 

  14. Chiba K, Tsuchiya M, Kato J, et al. Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers. Antimicrob Agents Chemother. 1989;33:1188–92.

    PubMed  CAS  Google Scholar 

  15. Yost RL, Derendorf H. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit. 1986;8:189–94.

    Article  PubMed  CAS  Google Scholar 

  16. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacother. 2007;27:1081–91.

    Article  CAS  Google Scholar 

  17. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet. 2000;38:415–26.

    Article  PubMed  CAS  Google Scholar 

  18. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89–96.

    Article  PubMed  CAS  Google Scholar 

  19. Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther. 2000;22:66–75.

    Article  PubMed  CAS  Google Scholar 

  20. Hermsen ED, Maiefski M, Florescu MC, et al. Comparison of the modification of diet in renal disease and Cockcroft–Gault equations for dosing antimicrobials. Pharmacotherapy. 2009;29:649–55.

    Article  PubMed  CAS  Google Scholar 

  21. Nguyen NT, Dakin G, Needleman B, et al. Effect of staple height on gastrojejunostomy during laparoscopic gastric bypass: a multicenter prospective randomized trial. Surg Obes Relat Dis. 2010;6:477–82.

    Article  PubMed  Google Scholar 

  22. Topaloglu S, Avsar FM, Ozel H, et al. Comparison of bariatric and non-bariatric elective operations in morbidly obese patients on the basis of wound infection. Obes Surg. 2005;15:1271–6.

    Article  PubMed  Google Scholar 

  23. Hospital-Acquired Conditions. [Website]: Centers for Medicare & Medicaid Services, 7500 Security Boulevard Baltimore, MD; 2010 [cited 2010 March 15]; Hospital-Acquired Conditions]. Available from: http://www.cms.hhs.gov/HospitalAcqCond/06_Hospital-Acquired_Conditions.asp.

  24. Chopra T, Zhao JJ, Alangaden G, et al. Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens. Expert Rev Pharmacoecon Outcomes Res. 2010;10:317–28.

    Article  PubMed  Google Scholar 

  25. Gonzalez R, Sarr MG, Smith CD, et al. Diagnosis and contemporary management of anastomotic leaks after gastric bypass for obesity. J Am Coll Surg. 2007;204:47–55.

    Article  PubMed  Google Scholar 

  26. Kermarrec N, Marmuse JP, Faivre J, et al. High mortality rate for patients requiring intensive care after surgical revision following bariatric surgery. Obes Surg. 2008;18:171–8.

    Article  PubMed  Google Scholar 

  27. Patel S, Szomstein S, Rosenthal RJ. Reasons and outcomes of reoperative bariatric surgery for failed and complicated procedures (excluding adjustable gastric banding). Obes Surg. 2011;21:1209–19.

    Article  PubMed  Google Scholar 

  28. Angrisani L, Furbetta F, Doldi SB, et al. Lap band adjustable gastric banding system: the Italian experience with 1863 patients operating on 6 years. Surg Endosc. 2003;17:409–12.

    Article  PubMed  CAS  Google Scholar 

  29. Bercault N, Boulain T, Kuteifan K, et al. Obesity-related excess mortality rate in an adult intensive care unit: a risk-adjusted matched cohort study. Crit Care Med. 2004;32:998–1003.

    Article  PubMed  Google Scholar 

  30. Fry DE. The importance of antibiotic pharmacokinetics in critical illness. Am J Surg. 1996;172:20S–5S.

    Article  PubMed  CAS  Google Scholar 

  31. Mann HJ, Buchwald H. Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients. Drug Intell Clin Pharm. 1986;20:869–73.

    PubMed  CAS  Google Scholar 

  32. Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992;36:552–7.

    PubMed  CAS  Google Scholar 

  33. Chen M, Nafziger AN, Drusano GL, et al. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal weight, obese, and extremely obese adults. Antimicrob Agents Chemother. 2006;50:1222–7.

    Article  PubMed  CAS  Google Scholar 

  34. Freeman JT, Anderson DJ, Hartwig MG, et al. Surgical site infections following bariatric surgery in community hospitals: a weighty concern? Obes Surg. 2010;21(7):836–40.

    Article  Google Scholar 

  35. Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt). 2012 (in press).

  36. Mutnick AH, Rhomberg PR, Sader HS, et al. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999–2001). J Antimicrob Chemother. 2004;53:290–6.

    Article  PubMed  CAS  Google Scholar 

  37. US Food and Drug Administration. Maxipime (cefepime hydrochloride) for injection. NDA 50-679/S021. http://www.fda.gov/medwatch/SAFETY/2003/03MAR_PI/Maxipime_PI.pdf.

  38. Alfandari S, Bonenfant C, Depretere L, et al. Use of 27 parenteral antimicrobial agents in north of France hospitals. Med Mal Infect. 2007;37:103–7.

    Article  PubMed  CAS  Google Scholar 

  39. Sader HS, Fritsche TR, Jones RN. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998–2003). Siagn Microbiol Infect Dis. 2005;52:265–73.

    Article  Google Scholar 

  40. Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect. 2002;8:823–5.

    Article  PubMed  CAS  Google Scholar 

  41. Sanders Jr WE, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis. 1996;23:454–61.

    Article  PubMed  CAS  Google Scholar 

  42. Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–48.

    Article  PubMed  CAS  Google Scholar 

  43. Barie PS, Hydo LJ, Larone DH, et al. Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect (Larchmt). 2005;6:41–54.

    Article  Google Scholar 

  44. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10.

    Article  PubMed  CAS  Google Scholar 

  45. Crandon JL, Bulik CC, Kuti JL, et al. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:1111–6.

    Article  PubMed  CAS  Google Scholar 

  46. Georges B, Conil JM, Cougot P, et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther. 2005;43:360–9.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Surgical Infection Society Foundation/Wyeth Fellowship in Clinical Evaluative Science (VPH).

Conflicts of Interest

All authors declare no conflicts of interest or financial disclosures.

Author information

Authors and Affiliations

  1. Department of Surgery, NewYork–Presbyterian Hospital/Weill Cornell Medical Center, 525 East 68 Street, Box 207, New York, NY, 10065, USA

    Barrie S. Rich, Vanessa P. Ho, Harma Turbendian, Cheguevara I. Afaneh, Gregory F. Dakin, Alfons Pomp & Philip S. Barie

  2. Department of Public Health, Weill Cornell Medical College, New York, NY, USA

    Philip S. Barie

  3. The Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA

    Rebecca Keel & David P. Nicolau

Authors
  1. Barrie S. Rich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca Keel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vanessa P. Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harma Turbendian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cheguevara I. Afaneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gregory F. Dakin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alfons Pomp
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David P. Nicolau
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Philip S. Barie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barrie S. Rich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rich, B.S., Keel, R., Ho, V.P. et al. Cefepime Dosing in the Morbidly Obese Patient Population. OBES SURG 22, 465–471 (2012). https://doi.org/10.1007/s11695-011-0586-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-011-0586-8

Keywords

Search

Navigation